Physician profile
Charina M Ramirez
NPI 1083792105
$59,947.37
in general payments reported to CMS, 2019-2025
17 companies · $10K in 2025
The $10K reported for 2025 was more than what 93% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $7,636 · 2021: $6,254 · 2022: $5,508 · 2023: $4,171 · 2024: $10K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Food and Beverage: $2,642 · Travel and Lodging: $1,327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,700.00 |
| Food and Beverage | $2,642.43 |
| Travel and Lodging | $1,326.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $33,059.96 | 2019-2023 | Cholbam |
| Mirum Pharmaceuticals, INC. | $20,012.26 | 2023-2025 | Livmarli, Cholbam, Cholbam |
| Alexion Pharmaceuticals, INC. | $4,934.25 | 2019-2022 | |
| Abbvie INC. | $507.86 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $296.96 | 2020-2025 | Gattex, Eohilia |
| Janssen Biotech, INC. | $262.32 | 2019-2023 | Stelara |
| Qol Medical, LLC | $248.29 | 2020-2023 | Sucraid |
| Genzyme Corporation | $192.71 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $163.46 | 2022-2025 | Dupixent |
| Perspectum Diagnostics LTD | $84.06 | 2022 | |
| Nestle Healthcare Nutrition INC. | $41.95 | 2021-2022 | |
| Pharming Healthcare, INC. | $33.40 | 2023-2024 | Ruconest |
| Intrabio INC | $26.72 | 2025 | Aqneursa |
| Aimmune Therapeutics, INC. | $24.50 | 2025 | Zenpep |
| Mauna Kea Technologies, INC. | $23.86 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcresta Therapeutics, INC. | $19.93 | 2023 | Relizorb |
| Ipsen Biopharmaceuticals, INC | $14.88 | 2024 | Bylvay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charina Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.